COPDPROMETENCT02499068
Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring
A study testing Telehealth in people with COPD and Disease Progression, run by Arturo Garcia at 5 sites in Spain.
Trial summary
The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period… Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- COPD, Disease Progression
- What is being tested?
- Telehealth
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 237 participants
- Where
- 5 sitesSpain
- Study dates
- Dec 2013to 1 Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Being over 50 and under 90 years of age.
- Being diagnosed with COPD according to the criteria of GesEPOC, with severe airflow obstruction defined as a forced expiratory volume in one second (FEV1) less than 50% of theoretical.
- "Exacerbator phenotype" defined as COPD patients having two or more moderate or severe exacerbations per year (GesEPOC guide). These exacerbations should be separated by at least 4 weeks after the end of previous treatment or 6 weeks from the start in cases that have not been treated
- Clinically stable condition, defined as 6 weeks without clinical symptoms since the last exacerbation of COPD.
- Having home oxygen therapy.
- Sign the informed consent.
Who cannot join
- Inability of the patient or caregiver to understand the procedure of Telehealth program.
- Have a life expectancy of less than one year.
- Have terminal heart failure (NYHA functional class III-IV).
- Having advanced renal insufficiency (creatinine clearance <30%) or be on dialysis program.
- Have liver cirrhosis or be included in a program of liver transplantation.
- Be institutionalized or in Residential hospice care.
Show all 9Show fewer
- Having a mini-mental test-score less than 24, because this score suggests dementia
- To be considered by your doctor as not comply the treatment or monitoring required by their lung disease.
- Failure to meet any of the inclusion criteria.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Spain5 sites
Hospital Universitario La Princesa
Madrid, 28006
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital Universitario La Paz
Madrid, 28046
Hospital Universitario Rey Juan Carlos
Madrid, 28933
About this study
Official title: Proyecto Madrileño Sobre el Manejo de la Enfermedad Pulmonar Obstructiva Crónica Con Telemonitorización a Domicilio. (Multicentre Project on the Home Telemonitoring of Patients With Severe Chronic Obstructive Pulmonary Disease).
The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period
The primary endpoint of effectiveness is "severe exacerbations avoided."
The main hypothesis is that patients with severe or very severe COPD patients managed with a home telehealth program have better outcomes than patients managed according to usual clinical practice.
Read the detailed description
Randomized, controlled, multicenter, performance, cost assessment and economic evaluation clinical trial. An arm of the trial will consist of patients assigned to the intervention group (telehealth group: TG ), and the other arm will consist of patients randomized to the control group (routine clinical practice: RCP).
For the economic evaluation, the perspective of the health system will be used. Therefore it only direct costs will be considered. In the TG arm also intervention costs it will be considered.
Patient selection:
Responsible researcher at each hospital center will coordinate the patient selection process. The researchers will identify candidate patients screening through hospital medical records.
After this first screening, patients will be contacted and invited to participate in the study. In a personal interview, the researcher explains the study to the patient and deliver the information sheet, verifying that patient meets all inclusion/exclusion criteria, obtains informed consent and then proceeds to patient randomization. To avoid bias from exclusions, researchers will hold record with patient exclusion causes.
Every hospital centers will include on average 60 patients (30 in each arm). The inclusion of patients will be competitive; having centers including patients in the study until reaching the final sample size of 120 patients per arm.
Randomization:
To avoid selection bias, patients assigned to each group will be randomized. To ensure that the number of subjects in each arm is the same, a restrictive block randomization is performed. Randomization is performed using random number generation by computer and the block size of 10 units.
Home Telehealth program:
Vital sign devices being used: spirometer, pulse oximeter with capacity for heart rate monitor, blood pressure, Visionox® (device capable of measuring respiratory rate, compliance with the hours of oxygen, and the flow and pattern of oxygen used).
Devices send data automatically to a modem by Bluetooth. Modem receives and transmits data simultaneously from the monitoring devices to a Central Monitoring Center (CMC). Data received by the modem are encrypted and sent to the telehealth monitoring platform via a 3G signal.
The CMC is manned by registered nurses and operates during office hours, 7 days a week.
Nurses will attend the patient's home for: the installation of the telehealth devices; to perform a thorough training of the patients / caregivers in the use of equipment and the COPD telehealth program.
Patients will perform daily vital sign measurements at the same time, at rest, after administration of the medication and the pattern of oxygen used. Visionox® performs measurements of respiratory rate and oxygen adherence automatically.
Measured data will be monitored on a daily bases by the nurses at the CMC. CMC will follow-up information, filter for fle positives and false negatives, and use an application acting as a traffic light system:
- Green: meant that measurements had been taken and were within the predefined limits, and no further action was required.
- Yellow: "technical alert". This means that the measurements had not been taken or had not been received. This alert could lead to a "clinical alert" due to a lack of adherence or discouragement. When the parameters were not received the nurse at the CMC called the patient to find the reason behind the alert, and either ruled out medical causes or, if one, notified the researcher leading the study.
- Red: "clinical alert". Meant that a measurement exceeded the limits that were previously preestablished for each.
Classification of severity of clinical alerts is performed by the CMC according to an algorithm. Depending n severity different early medical interventions are taken, or escalated to clinical responsible for early intervention.
- Conditions
- COPD, Disease Progression
- Being tested
- Telehealth
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Disease Progression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TelehealthDevice
Also called Telemedicine
Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
| Study group | Role | What they receive |
|---|---|---|
| COPD, Telehealth | Experimental | Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention. Receives: Device: Telehealth |
| COPD, Normal clinical practice | No intervention | Patients would do the usual clinical practice. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of hospitalizations due to exacerbation of COPD avoided
Measured: 1 year
Secondary outcomes (3)
Cost-efficiency of treatment
Measured: 1 year
Cost-utility of treatment
Measured: 1 year
satisfaction of both patients and clinician responsibility questionnaire
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2015 (estimated)
- Study startDec 2013
- Primary completion1 Jun 2016
- Study completion1 Jun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for COPDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 237 participants (actual)
Sponsor and investigators
- Lead sponsor
- Arturo Garcia
- Sponsor type
- University, hospital or other
- Collaborators
- Linde Health Care, Técnicas Avanzadas de Investigación en Servicios de Salud TAISS, Syreon Corporation
- Responsible party
- Sponsor-investigator, Arturo Garcia, Fundación Teófilo Hernando, Spain
- Investigators
- Julio Ancochea Bermúdez, MD, PhD, Principal investigator, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02499068
- Sponsor's protocol ID
- PROMETE
- Acronym
- PROMETE
- Status last verified
- Aug 2019
- First submitted
- 20 Mar 2015
- Last updated
- 6 Aug 2019
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Segrelles Calvo G, Gomez-Suarez C, Soriano JB, Zamora E, Gonzalez-Gamarra A, Gonzalez-Bejar M, Jordan A, Tadeo E, Sebastian A, Fernandez G, Ancochea J. A home telehealth program for patients with severe COPD: the PROMETE study. Respir Med. 2014 Mar;108(3):453-62. doi: 10.1016/j.rmed.2013.12.003. Epub 2013 Dec 16.
PubMed 24433744Ancochea J, Garcia-Rio F, Vazquez-Espinosa E, Hernando-Sanz A, Lopez-Yepes L, Galera-Martinez R, Peces-Barba G, Perez-Warnisher MT, Segrelles-Calvo G, Zamarro C, Gonzalez-Ponce P, Ramos MI, Conforto JI, Jafri S, Soriano JB. Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Eur Respir J. 2018 May 30;51(5):1800354. doi: 10.1183/13993003.00354-2018. Print 2018 May. No abstract available.
PubMed 29599185
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proyecto Madrileño Sobre el Manejo de la Enfermedad Pulmonar Obstructiva Crónica Con Telemonitorización a Domicilio. (Multicentre Project on the Home Telemonitoring of Patients With Severe Chronic Obstructive Pulmonary Disease).
- ClinicalTrials.gov ID
- NCT02499068
- Acronym / sponsor ID
- PROMETE / PROMETE
- Conditions
- COPD, Disease Progression
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 237 participants (actual)
- Lead sponsor
- Arturo GarciaUniversity, hospital or other
- Collaborators
- Linde Health Care, Técnicas Avanzadas de Investigación en Servicios de Salud TAISS, Syreon Corporation
- Study start
- Dec 2013
- Primary completion
- 1 Jun 2016 (actual)
- Study completion
- 1 Jun 2016 (actual)
- First posted
- 15 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to verify the clinical effectiveness of a managed home telemonitoring program in patients with severe COPD against usual clinical practice, as measured by the decrease in the number of exacerbations, number of hospitalizations, hospital days and emergency room visits in a 12 month period
The primary endpoint of effectiveness is "severe exacerbations avoided."
The main hypothesis is that patients with severe or very severe COPD patients managed with a home telehealth program have better outcomes than patients managed according to usual clinical practice.
Detailed description
Randomized, controlled, multicenter, performance, cost assessment and economic evaluation clinical trial. An arm of the trial will consist of patients assigned to the intervention group (telehealth group: TG ), and the other arm will consist of patients randomized to the control group (routine clinical practice: RCP).
For the economic evaluation, the perspective of the health system will be used. Therefore it only direct costs will be considered. In the TG arm also intervention costs it will be considered.
Patient selection:
Responsible researcher at each hospital center will coordinate the patient selection process. The researchers will identify candidate patients screening through hospital medical records.
After this first screening, patients will be contacted and invited to participate in the study. In a personal interview, the researcher explains the study to the patient and deliver the information sheet, verifying that patient meets all inclusion/exclusion criteria, obtains informed consent and then proceeds to patient randomization. To avoid bias from exclusions, researchers will hold record with patient exclusion causes.
Every hospital centers will include on average 60 patients (30 in each arm). The inclusion of patients will be competitive; having centers including patients in the study until reaching the final sample size of 120 patients per arm.
Randomization:
To avoid selection bias, patients assigned to each group will be randomized. To ensure that the number of subjects in each arm is the same, a restrictive block randomization is performed. Randomization is performed using random number generation by computer and the block size of 10 units.
Home Telehealth program:
Vital sign devices being used: spirometer, pulse oximeter with capacity for heart rate monitor, blood pressure, Visionox® (device capable of measuring respiratory rate, compliance with the hours of oxygen, and the flow and pattern of oxygen used).
Devices send data automatically to a modem by Bluetooth. Modem receives and transmits data simultaneously from the monitoring devices to a Central Monitoring Center (CMC). Data received by the modem are encrypted and sent to the telehealth monitoring platform via a 3G signal.
The CMC is manned by registered nurses and operates during office hours, 7 days a week.
Nurses will attend the patient's home for: the installation of the telehealth devices; to perform a thorough training of the patients / caregivers in the use of equipment and the COPD telehealth program.
Patients will perform daily vital sign measurements at the same time, at rest, after administration of the medication and the pattern of oxygen used. Visionox® performs measurements of respiratory rate and oxygen adherence automatically.
Measured data will be monitored on a daily bases by the nurses at the CMC. CMC will follow-up information, filter for fle positives and false negatives, and use an application acting as a traffic light system:
- Green: meant that measurements had been taken and were within the predefined limits, and no further action was required.
- Yellow: "technical alert". This means that the measurements had not been taken or had not been received. This alert could lead to a "clinical alert" due to a lack of adherence or discouragement. When the parameters were not received the nurse at the CMC called the patient to find the reason behind the alert, and either ruled out medical causes or, if one, notified the researcher leading the study.
- Red: "clinical alert". Meant that a measurement exceeded the limits that were previously preestablished for each.
Classification of severity of clinical alerts is performed by the CMC according to an algorithm. Depending n severity different early medical interventions are taken, or escalated to clinical responsible for early intervention.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| COPD, Telehealth | Experimental | Device: TelehealthPatients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention. |
| COPD, Normal clinical practice | No intervention | –Patients would do the usual clinical practice. |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Being over 50 and under 90 years of age.
- Being diagnosed with COPD according to the criteria of GesEPOC, with severe airflow obstruction defined as a forced expiratory volume in one second (FEV1) less than 50% of theoretical.
- "Exacerbator phenotype" defined as COPD patients having two or more moderate or severe exacerbations per year (GesEPOC guide). These exacerbations should be separated by at least 4 weeks after the end of previous treatment or 6 weeks from the start in cases that have not been treated
- Clinically stable condition, defined as 6 weeks without clinical symptoms since the last exacerbation of COPD.
- Having home oxygen therapy.
Key exclusion criteria (9 listed)
- Inability of the patient or caregiver to understand the procedure of Telehealth program.
- Have a life expectancy of less than one year.
- Have terminal heart failure (NYHA functional class III-IV).
- Having advanced renal insufficiency (creatinine clearance <30%) or be on dialysis program.
- Have liver cirrhosis or be included in a program of liver transplantation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TelehealthAlso: TelemedicineMonitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention. | Device | COPD, Telehealth |
Primary outcome
Number of hospitalizations due to exacerbation of COPD avoided
Time frame: 1 year
3 secondary outcomes
Cost-efficiency of treatment
Time frame: 1 year
Cost-utility of treatment
Time frame: 1 year
satisfaction of both patients and clinician responsibility questionnaire
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2019.
- Background: PubMed 24433744Segrelles Calvo G, Gomez-Suarez C, Soriano JB, Zamora E, Gonzalez-Gamarra A, Gonzalez-Bejar M, Jordan A, Tadeo E, Sebastian A, Fernandez G, Ancochea J. A home telehealth program for patients with severe COPD: the PROMETE study. Respir Med. 2014 Mar;108(3):453-62. doi: 10.1016/j.rmed.2013.12.003. Epub 2013 Dec 16.
- Derived from this study: PubMed 29599185Ancochea J, Garcia-Rio F, Vazquez-Espinosa E, Hernando-Sanz A, Lopez-Yepes L, Galera-Martinez R, Peces-Barba G, Perez-Warnisher MT, Segrelles-Calvo G, Zamarro C, Gonzalez-Ponce P, Ramos MI, Conforto JI, Jafri S, Soriano JB. Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Eur Respir J. 2018 May 30;51(5):1800354. doi: 10.1183/13993003.00354-2018. Print 2018 May. No abstract available.
Related trials for COPD
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julio Ancochea Bermúdez, MD, PhD principal investigator
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Telehealth in people with COPD and Disease Progression, run by Arturo Garcia at 5 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of hospitalizations due to exacerbation of COPD avoided (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02499068, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2019.